Natalie Brousseau recently earned her PhD in Human Development & Family Sciences from the University of Delaware and will soon begin a post-doctoral fellowship at the University of Connecticut. Natalie, Valerie, and Carly chat about their work on the UDisclose study, which focused on understanding disclosure experiences among people in recovery from opioid use disorders in Delaware. Natalie shares the results of her three dissertation studies, and Valerie and Carly wish Natalie good luck in her next round of science adventures.

This is our last episode of the season. Follow us on instagram @sexdrugsscience to stay up to date on future episodes. 

Sarah Calabrese is an Assistant Professor of clinical psychology at The George Washington University. Her research focuses on sexual health promotion among racial and sexual minorities and other socially marginalized groups. Sarah chats with Valerie about all things PrEP (an HIV prevention medication), including: how many people are (or aren’t) using PrEP, (arguably) conservative guidelines around PrEP recommendations, and provider bias in PrEP prescription that likely leads to inequities in who can access PrEP. Valerie asks Sarah about why it’s important to think about sexual pleasure when we’re studying HIV prevention and sexual health promotion. 

Learn more about Sarah’s work here: https://shel.columbian.gwu.edu/

Dave Humes is a Board Member and the Public Policy Coordinator of aTAcK addiction, a naloxone trainer, and co-chair of the Changing Perceptions and Stigma Subcommittee of the Behavioral Health Consortium In Delaware. Dave shares his story of losing his son to an opioid overdose, and how that inspired him to advocate for policy change surrounding access to naloxone (an opioid overdose-reversal medication) in Delaware. Valerie and Carly ask Dave for advice about advocating for policy change and Dave shares advice for scientists. 

Learn more about aTAcK addiction here: https://www.attackaddiction.org/
Follow Dave on Twitter: @Gregs_Dad

Learn more about how naloxone laws changed between 2001 and 2017 through the Prescription Drug Policy System site: https://pdaps.org/